0.50Open0.50Pre Close0 Volume13 Open Interest17.50Strike Price0.00Turnover506.33%IV350.56%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.2764Delta0.0684Gamma7.99Leverage Ratio-0.0384Theta0.0004Rho2.21Eff Leverage0.0032Vega
Larimar Therapeutics Stock Discussion
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
Monday, 16th December at 7:00 am
• Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study
• Tissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells a...
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...
No comment yet